NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure: PRIMA II Randomized Controlled Trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?)

What Was Tested

The paper reports a study of BNP (Nesiritide), published as a randomized controlled trial.

The effect of NT-proBNP (N-terminal probrain natriuretic peptide)-guided therapy in patients with acute decompensated HF using a relative NT-proBNP target has not been investigated.

Who Took Part

According to the abstract, 405 patients were involved.

PubMed indexes the participants as older adults and people over 80, both men and women.

Patients with acute decompensated HF with NT-proBNP levels >1700 ng/L were eligible.

After achieving clinical stability, 405 patients were randomized to either NT-proBNP-guided or conventional treatment (1:1).

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this BNP (Nesiritide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The methods mention a period of 180 days.

The primary end point was dual: a composite of all-cause mortality and HF readmissions in 180 days and the number of days alive out of the hospital in 180 days.

Secondary end points were all-cause mortality within 180 days, HF readmissions within 180 days, and a composite of all-cause mortality and HF readmissions within 90 days.

What Was Measured

PubMed files the paper under topics including Biomarkers, Clinical Decision-Making, Decision Support Techniques, Europe, Heart Failure, Natriuretic Peptide, Brain and Patient Readmission.

Author keywords: hospitalization, mortality and randomized controlled trial.

What This Means in Plain Language

The paper is a randomized study of BNP (Nesiritide) in 405 patients over 180 days.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2018 (Circulation), a journal based in United States.

More context: the BNP (Nesiritide) compound page, all human trials.